The Government of Catalonia appointed Biocat to lead a strategic initiative: to identify and connect all public and private stakeholders working in advanced therapies (ATMPs), and to promote the creation of a collaborative network that can align capabilities, coordinate efforts and boost the ecosystem’s collective impact. Acting as a neutral facilitator, Biocat was tasked with turning Catalonia’s scientific and clinical potential into a coordinated driver for innovation and patient access.
Catalonia’s collaborative hub
accelerating the impact of
advanced therapies across Europe
Why ATMP Catalonia?
Why ATMP Catalonia?
Where collaboration transforms vision into impact in advanced therapies
Since then, we have been driving this mission forward by:
Identifying strategic opportunities and promoting funding instruments that accelerate the development of ATMPs, enabling their transition from research to clinical application.
Strengthening public private partnership by building strategic consortia and shared projects across the entire ATMP value chain.
Fostering translational and clinical research in strategic areas to accelerate innovation and deliver meaningful impact for patients and society.
Positioning Catalonia internationally as a leading European hub for the development, manufacturing and adoption of advanced therapy medicinal products (ATMPs).
Our mission in action
Science with purpose to accelerate advanced therapies
ATMP Catalonia is building a leading European ecosystem for advanced therapies, defined by scientific excellence, industrial and clinical expertise, and fair patient access. As an inclusive, collaborative network, we attract talent and investment to turn cutting edge research into real treatments.
Our ambition is clear: to set the European benchmark in innovation, quality and transformative outcomes in cell and gene therapies.
Our path forward
Our path forward
Driving the future of cell and gene therapies
Advanced therapies continue to evolve rapidly, bringing unprecedented opportunities, but also complex challenges: from technology transfer and scalable manufacturing to talent specialization, regulatory pathways, long term monitoring, equitable access and financial sustainability.
